Eur Rev Med Pharmacol Sci 2022; 26 (23): 8728-8737
DOI: 10.26355/eurrev_202212_30545

Prognostic value of the C-reactive protein-to-albumin ratio in patients with infective endocarditis

D. Baykiz, E.A. Govdeli, Z.G. Demirtakan, A. Elitok, B. Umman, Z. Bugra

Department of Cardiology, Faculty of Medicine, Istanbul University, Istanbul, Turkey. derya.baykiz@hotmail.com


OBJECTIVE: Infective endocarditis (IE) is a life-threatening disease that causes various complications and mortality. The C-reactive protein-to-albumin ratio (CAR) has been reported as a novel prognostic marker in inflammatory and cardiovascular diseases. We retrospectively investigated whether there is a relationship between admission CAR values and prognosis in patients with IE.

PATIENTS AND METHODS: The study population was classified into 2 groups: patients with a primary clinical outcome (n = 64) and those without (n = 132). The primary clinical outcome consisted of the need for intensive care unit treatment and in-hospital mortality. For all patients, serum CAR levels at hospital admission were calculated.

RESULTS: In this study, 196 patients with a definite diagnosis of IE during a 5-year period were included. The mean age of the total patients was 52.7 ± 14.9 years (67% male, mean age 51.9 ± 15.0 years; 33% female, mean age 54.3 ± 14.4 years, respectively). Serum CAR values were associated with prognosis in IE patients. According to Cox regression analysis, admission CAR value remained an independent predictor of mortality (p < 0.05). In receiver operating curve analysis, a cutoff value of CAR > 20.24 predicted primary clinical outcome with a sensitivity of 82.4% and specificity of 70.3% (p < 0.001).

CONCLUSIONS: For the first time, the present study showed that in IE, admission CAR could be a useful predictor of poor prognosis, including hospital death.

Free PDF Download

To cite this article

D. Baykiz, E.A. Govdeli, Z.G. Demirtakan, A. Elitok, B. Umman, Z. Bugra
Prognostic value of the C-reactive protein-to-albumin ratio in patients with infective endocarditis

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 23
Pages: 8728-8737
DOI: 10.26355/eurrev_202212_30545